Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Gregory Y. H. Lip MD"'
Autor:
Yuanyuan Liu MD, Linjie Li MD, Jingge Li MD, Hangkuan Liu MD, A Geru MD, Yulong Wang MD, Yongle Li MD, PhD, Ching-Hui Sia MBBS, MRCP, Gregory Y. H. Lip MD, Qing Yang MD, PhD, Xin Zhou MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 30 (2024)
Background Intracranial haemorrhage (ICH) poses a significant threat to patients on Direct Oral Anticoagulants (DOACs), with existing risk scores inadequately predicting ICH risk in these patients. We aim to develop and validate a predictive model fo
Externí odkaz:
https://doaj.org/article/5d8698a547de4a1ab225de23fff57395
Autor:
Qinmei Xiong MD, PhD, Cen Wang MD, Hualong Liu MD, Zhaochong Tan MD, Chen Chen MD, Juxiang Li MD, Gregory Y. H. Lip MD, Kui Hong MD, PhD
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
There are few head-to-head trials directly comparing non-vitamin K antagonist oral anticoagulants (NOACs) against one other. A network meta-analysis (NMA) was performed to examine the indirect comparisons among NOACs in Asians with nonvalvular atrial
Externí odkaz:
https://doaj.org/article/29a65d59ee2544a6b421db7bb64863c9
Autor:
Jie Zeng MSc, Xuhui Zhang MD, Gregory Y. H. Lip MD, Xiaochen Shu MD, Lehana Thabane PhD, Junzhang Tian MD, Guowei Li PhD, MSc, MBBS
Publikováno v:
Clinical and Applied Thrombosis/Hemostasis, Vol 25 (2019)
Efficacy and safety of direct oral anticoagulants (DOACs) for preventing primary and recurrent venous thromboembolism (VTE) in patients with cancer remain unclear. In this study, we conducted a systematic review to summarize the most up-to-date evide
Externí odkaz:
https://doaj.org/article/c654cb7c261f4500a74d2da69f805886